NervGen Pharma Corp.
NGEN.VTSXVHealthcare
$5.15
+$0.15(+3.00%)
Market Cap$407944447
P/E Ratio—
52W High$8.49
52W Low$2.57
NervGen Pharma Corp. (NGEN.V) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
NGEN.V · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 13, 2026EPS Actual
-$0.37
Est. -$0.09 · -321.8%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 13, 2026
After Market Close
▼ Miss EPS
NGEN.V reports quarterly as a TSXV-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$1.19
Rev. $0.35B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$1.19
Rev. Est.$0.35B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 13, 2026 | -$0.09 | -$0.37 | -321.8% | — | — | — |
| ◌ Q2 FY2026 | Apr 2, 2026 | -$0.09 | — | — | — | — | — |
| ▲ Q4 FY2025 | Nov 25, 2025 | -$0.06 | -$0.06 | +5.3% | — | — | — |
| ▼ Q3 FY2025 | Aug 27, 2025 | -$0.06 | -$0.13 | -110.9% | — | — | — |
| ▲ Q2 FY2025 | May 14, 2025 | -$0.09 | -$0.06 | +33.3% | — | — | — |
| ▼ Q2 FY2025 | Apr 3, 2025 | -$0.08 | -$0.13 | -62.5% | — | — | — |
| ▲ Q4 FY2024 | Nov 14, 2024 | -$0.09 | -$0.07 | +22.2% | — | — | — |
| ▼ Q3 FY2024 | Aug 22, 2024 | -$0.09 | -$0.11 | -22.2% | — | — | — |
Q2 FY2026
May 13, 2026Miss
EPS Actual
-$0.37
EPS Est.
-$0.09
EPS Surpr.
-321.8%
Revenue
—
Q2 FY2026
Apr 2, 2026
EPS Actual
—
EPS Est.
-$0.09
EPS Surpr.
—
Revenue
—
Q4 FY2025
Nov 25, 2025Beat
EPS Actual
-$0.06
EPS Est.
-$0.06
EPS Surpr.
+5.3%
Revenue
—
Q3 FY2025
Aug 27, 2025Miss
EPS Actual
-$0.13
EPS Est.
-$0.06
EPS Surpr.
-110.9%
Revenue
—
Q2 FY2025
May 14, 2025Beat
EPS Actual
-$0.06
EPS Est.
-$0.09
EPS Surpr.
+33.3%
Revenue
—
Q2 FY2025
Apr 3, 2025Miss
EPS Actual
-$0.13
EPS Est.
-$0.08
EPS Surpr.
-62.5%
Revenue
—
Q4 FY2024
Nov 14, 2024Beat
EPS Actual
-$0.07
EPS Est.
-$0.09
EPS Surpr.
+22.2%
Revenue
—
Q3 FY2024
Aug 22, 2024Miss
EPS Actual
-$0.11
EPS Est.
-$0.09
EPS Surpr.
-22.2%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.11 | $-0.11 | $-0.11 | 1 |
| Q3 FY2027 | $-0.11 | $-0.11 | $-0.11 | 1 |
| Q2 FY2027 | $-0.10 | $-0.10 | $-0.10 | 1 |
| Q1 FY2027 | $-0.11 | $-0.11 | $-0.11 | 1 |
| Q4 FY2026 | $-0.11 | $-0.11 | $-0.11 | 1 |
| Q3 FY2026 | $-0.10 | $-0.10 | $-0.10 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 13, 2026 | -321.8% | $5.15 | — | — |
| ▲ Q4 FY2025 | Nov 25, 2025 | +5.3% | $4.45 | $4.38 | -1.57% |
| ▼ Q3 FY2025 | Aug 27, 2025 | -110.9% | $3.55 | $3.32 | -6.48% |
| ▲ Q2 FY2025 | May 14, 2025 | +33.3% | $3.64 | $3.60 | -1.10% |
| ▼ Q2 FY2025 | Apr 3, 2025 | -62.5% | $3.30 | $3.09 | -6.36% |
| ▲ Q4 FY2024 | Nov 14, 2024 | +22.2% | $2.68 | $2.18 | -18.66% |
| ▼ Q3 FY2024 | Aug 22, 2024 | -22.2% | $2.85 | $2.82 | -1.05% |
| ▲ Q2 FY2024 | Apr 23, 2024 | +57.6% | $2.13 | $2.06 | -3.29% |
Q2 FY2026—
Report Date
May 13, 2026
EPS Beat/Miss
-321.8%
Price Before
$5.15
Price After
—
Q4 FY2025-1.57%
Report Date
Nov 25, 2025
EPS Beat/Miss
+5.3%
Price Before
$4.45
Price After
$4.38
Q3 FY2025-6.48%
Report Date
Aug 27, 2025
EPS Beat/Miss
-110.9%
Price Before
$3.55
Price After
$3.32
Q2 FY2025-1.10%
Report Date
May 14, 2025
EPS Beat/Miss
+33.3%
Price Before
$3.64
Price After
$3.60
Q2 FY2025-6.36%
Report Date
Apr 3, 2025
EPS Beat/Miss
-62.5%
Price Before
$3.30
Price After
$3.09
Q4 FY2024-18.66%
Report Date
Nov 14, 2024
EPS Beat/Miss
+22.2%
Price Before
$2.68
Price After
$2.18
Q3 FY2024-1.05%
Report Date
Aug 22, 2024
EPS Beat/Miss
-22.2%
Price Before
$2.85
Price After
$2.82
Q2 FY2024-3.29%
Report Date
Apr 23, 2024
EPS Beat/Miss
+57.6%
Price Before
$2.13
Price After
$2.06
Avg Beat Reaction-6.15%
Avg Miss Reaction-4.63%
Beat Rate4 / 8 quarters
Largest Move-18.66% (Q4 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: NGEN.V ends December
NervGen Pharma Corp. (NGEN.V) most recently reported earnings on May 13, 2026 for Q2 FY2026, posting EPS of $-0.37 — missing the analyst consensus of $-0.09 by -321.8%. The next NGEN.V earnings date is expected around September 1, 2026.
Each quarter, investors track NGEN.V earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. NGEN.V revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
NGEN.V's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
NGEN.V earnings · 5 questionsNervGen Pharma Corp.'s next earnings report is expected around September 1, 2026. NGEN.V typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; NGEN.V historically reports after market close (AMC).
NGEN.V earnings datewhen is NGEN.V earningsNGEN.V next earnings datewhen does NGEN.V report earningsNGEN.V earnings calendar
▸ Source: FMP · NervGen Pharma Corp. SEC filings · US GAAP · NervGen Pharma Corp. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026